The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRα-positive hypereosinophilic syndrome. Results of a multicenter prospective study

Background and Objectives The hypereosinophilic syndrome (HES) may be associated with the fusion of the platelet derived growth factor receptor α (PDGFRα) gene with the FIP1L1 gene in chromosome 4 coding for a constitutively activated PDGFRα tyrosine kinase. These cases with FIP1L1-PDGFRα rearrangement have been reported to be very sensitive to the tyrosine kinase inhibitor imatinib mesylate. Design and Methods A prospective multicenter study of idiopathic or primary HES was established in 2001 (Study Protocol Registration no. NCT 0027 6929). One hundred and ninety-six patients were screened, of whom 72 where identified as having idiopathic or primary HES and 63 were treated with imatinib 100 to 400 mg daily. Results Twenty-seven male patients carried the FIP1L1-PDGFRα rearrangement. All 27 achieved a complete hematologic remission (CHR) and became negative for the fusion transcripts according to reverse transcriptase polymerase chain reaction (RT-PCR) analysis. With a median follow-up of 25 months (15–60 months) all 27 patients remain in CHR and RT-PCR negative, and continue treatment at a dose of 100 to 400 mg daily. In three patients imatinib treatment was discontinued for few months, the fusion transcript became rapidly detectable, and then again undetectable upon treatment reassumption. Thirty-six patients did not carry the rearrangement; of these, five (14%) achieved a CHR, which was lost in all cases after 1 to 15 months. Interpretation and Conclusions All patients meeting the criteria for idiopathic or primary HES should be screened for the FIP1L1-PDGFRα rearrangement. For all patients with this rearrangement, chronic imatinib treatment at doses as low as 100 mg daily ensures complete and durable responses.

[1]  M. Baccarani,et al.  FIP1L1-PDGFRalpha Positive Hypereosinophilic Syndrome (HES). The Response to Imatinib (IM) Is Durable. A Report of 21 Patients with a Follow-Up of 12 to 67 Months. , 2006 .

[2]  A. Tefferi,et al.  FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. , 2006, Leukemia research.

[3]  Brian Walters,et al.  Cardiotoxicity of the cancer therapeutic agent imatinib mesylate , 2006, Nature Medicine.

[4]  A. Reiter,et al.  The results of imatinib therapy for patients with primary eosinophilic disorders , 2006, European journal of haematology.

[5]  Glenn Heller,et al.  Altered bone and mineral metabolism in patients receiving imatinib mesylate. , 2006, The New England journal of medicine.

[6]  M. Baccarani,et al.  Imatinib Mesylate Can Induce Molecular Complete Remission in Idiopathic Hypereosinophilic Syndrome (HES). A Phase II Multicentric Italian Clinical Trial. , 2005 .

[7]  B. Quesnel,et al.  Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics , 2005, Leukemia.

[8]  A. Tefferi,et al.  FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. , 2004, Blood.

[9]  G. Webersinke,et al.  p53-Binding Protein 1 Is Fused to the Platelet-Derived Growth Factor Receptor β in a Patient with a t(5;15)(q33;q22) and an Imatinib-Responsive Eosinophilic Myeloproliferative Disorder , 2004, Cancer Research.

[10]  Ayalew Tefferi,et al.  Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. , 2004, Blood.

[11]  S. Gottschalk,et al.  Imatinib (STI571)-Mediated Changes in Glucose Metabolism in Human Leukemia BCR-ABL-Positive Cells , 2004, Clinical Cancer Research.

[12]  A. la Sala,et al.  Heterogeneity of Response to Imatinib-Mesylate (Glivec) in Patients with Hypereosinophilic Syndrome: Implications for Dosing and Pathogenesis , 2004, Leukemia & lymphoma.

[13]  D. Gary Gilliland,et al.  The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management , 2004 .

[14]  D. Gilliland,et al.  Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias , 2004, Leukemia.

[15]  M. Baccarani,et al.  Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. , 2004, Blood.

[16]  C. Preudhomme,et al.  Sustained molecular response with imatinib in a leukemic form of idiopathic hypereosinophilic syndrome in relapse after allograft , 2004, Leukemia.

[17]  D. Metcalfe,et al.  Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. , 2004, Blood.

[18]  D. Gilliland,et al.  CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. , 2003, Blood.

[19]  D. Gilliland,et al.  Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. , 2003, Blood.

[20]  H. Kantarjian,et al.  Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. , 2003, Blood.

[21]  Peter Marynen,et al.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. , 2003, The New England journal of medicine.

[22]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[23]  S. Kulkarni,et al.  Novel translocations that disrupt the platelet‐derived growth factor receptor β (PDGFRB) gene in BCR–ABL‐negative chronic myeloproliferative disorders , 2003, British journal of haematology.

[24]  H. Kantarjian,et al.  Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. , 2002, Leukemia research.

[25]  B. Bain,et al.  Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. , 2002, The New England journal of medicine.

[26]  A. Reiter,et al.  Tyrosine kinase fusion genes in chronic myeloproliferative diseases , 2002, Leukemia.

[27]  Nicholas C P Cross,et al.  The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. , 2002, Human molecular genetics.

[28]  A. Tefferi,et al.  Treatment of hypereosinophilic syndrome with imatinib mesilate , 2002, The Lancet.

[29]  E. Macintyre,et al.  Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease , 1999, Leukemia.

[30]  M. Carroll,et al.  CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. , 1997, Blood.

[31]  J. Melo,et al.  Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. , 2007, Blood.

[32]  R. Piazza,et al.  In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate' , 2007, Nature Medicine.

[33]  H. Kantarjian,et al.  In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate' , 2007, Nature Medicine.

[34]  U. Martens,et al.  Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature , 2005, Annals of Hematology.

[35]  P. Marynen,et al.  The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases. , 2005, Haematologica.

[36]  B. Bain.  The idiopathic hypereosinophilic syndrome and eosinophilic leukemias. , 2004, Haematologica.

[37]  M. Baccarani,et al.  Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome. , 2004, Haematologica.

[38]  P. Zalloua,et al.  Effective treatment of hypereosinophilic syndrome with imatinib mesylate. , 2003, The hematology journal : the official journal of the European Haematology Association.

[39]  E. Baxter,et al.  Imatinib therapy for hypereosinophilic syndrome and other eosinophilic , 2003 .

[40]  T. Meyer,et al.  Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. , 1996, Cancer research.

[41]  A. Hagenbeek,et al.  Minimal Residual Disease in Acute Leukemia , 1984, Developments in Oncology.

[42]  Iscn.  International System for Human Cytogenetic Nomenclature , 1978 .